Please login to the form below

Not currently logged in
Email:
Password:

Bristol Myers Squibb

This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.

BMS eyes approval for second Opdivo combo in kidney cancer

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... Botwood, vice president, interim head,

Latest news

More from news
Approximately 161 fully matching, plus 913 partially matching documents found.

Latest Intelligence

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    2. Ozanimod, developed by Bristol-Myers Squibb, is an orally delivered agonist of sphingosine-1- phosphate type 1 (S1P1) and S1P5 receptors, two proteins with a pivotal role in the trafficking ... 11. Liso-cel for large B-cell lymphoma is being developed

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers Squibb when its $74bn

More from intelligence
Approximately 4 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics